about
Changes in translational control after pro-apoptotic stressmTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic InterventionsEIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinomaPharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1Eukaryotic Translation Initiation Factor 4E Is a Feed-Forward Translational Coactivator of Transforming Growth Factor β Early Protransforming Events in Breast Epithelial Cells.Cyclin B Translation Depends on mTOR Activity after Fertilization in Sea Urchin Embryos.mTOR coordinates protein synthesis, mitochondrial activity and proliferation.Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma4E-BP1 participates in maintaining spindle integrity and genomic stability via interacting with PLK1.eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer4E-BP restrains eIF4E phosphorylationThe PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.4E-BP1, a multifactor regulated multifunctional proteinMitotic protein kinase CDK1 phosphorylation of mRNA translation regulator 4E-BP1 Ser83 may contribute to cell transformationTotal 4EBP1 Is Elevated in Liver of Rats in Response to Low Sulfur Amino Acid Intake.4EGI-1 induces apoptosis and enhances radiotherapy sensitivity in nasopharyngeal carcinoma cells via DR5 induction on 4E-BP1 dephosphorylationThe Role of Dynamics and Allostery in the Inhibition of the eIF4E/eIF4G Translation Initiation Factor Complex4EBP-Dependent Signaling Supports West Nile Virus Growth and Protein Expression.Targeting translation: eIF4E as an emerging anticancer drug target.mTOR kinase inhibitor pp242 causes mitophagy terminated by apoptotic cell death in E1A-Ras transformed cellsTargeting of protein translation as a new treatment paradigm for prostate cancer.mTORC1 signaling in primary central nervous system lymphoma.PD-1 Checkpoint Blockade in Combination with an mTOR Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1.A unique binding mode of the eukaryotic translation initiation factor 4E for guiding the design of novel peptide inhibitors.New insights into 4E-BP1-regulated translation in cancer progression and metastasis.Expression of eukaryotic initiation factor 4E and 4E binding protein 1 in colorectal carcinogenesis.Targeting protein synthesis in cancer cells4E-BPs require non-canonical 4E-binding motifs and a lateral surface of eIF4E to repress translation.Mextli proteins use both canonical bipartite and novel tripartite binding modes to form eIF4E complexes that display differential sensitivity to 4E-BP regulation.Downregulation of microRNA-15a suppresses the proliferation and invasion of renal cell carcinoma via direct targeting of eIF4E.Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1.Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL.High-Throughput Chemical Probing of Full-Length Protein-Protein Interactions.Pancreatic tumours escape from translational control through 4E-BP1 loss.eIF4E-binding proteins: new factors, new locations, new rolesThe Role of Dynamics and Allostery in the Inhibition of the eIF4E/eIF4G Translation Initiation Factor Complex
P2860
Q26863275-06A9C19B-00E4-49D0-ABC1-BAF633855733Q27007511-0257CA60-2ACD-4FF9-AEB5-5B861B29FE07Q35058443-C17355C1-AA90-477D-9492-458DE091153EQ35695360-F82CB474-C39D-40D3-AB94-7E3312675E87Q35909996-7FC2154D-D303-4B23-9595-D1E7EB4F0EE2Q35914014-BF8228D8-D196-45BA-9377-A2995B173354Q35952095-489682FF-5DCF-42D2-AF62-422D99CEF35AQ36189549-97864EBE-3B0B-4032-9C44-4F991787E699Q36250674-B6DF9EED-BE05-4FC1-9FD1-554CC757C438Q36304185-2C0E8F25-7C08-48A5-944C-20B76FD7155AQ36414386-9E3D922D-C51E-4696-A9AF-45888897A59BQ36477529-2DD2E085-2B6C-4927-91D3-8B17CA071E83Q36545566-34008368-F813-4DFE-9320-B9C375E8D342Q36838384-8B98595A-835C-4D55-86A1-1121EAB97D4DQ37142826-15698508-DC4B-4214-9B73-ABF7A30917ADQ37195002-EBB148F1-96FA-4CAA-817B-1998B813BC8DQ37225382-4B7298B9-C94D-4006-A694-AA22661E1265Q37255081-18761A71-E800-4EAA-A957-ADB8856183B4Q37378827-14FFF09C-B0CD-4ACD-A0EC-2072B42E7C19Q38699320-C0232D9F-20DA-4EB2-A76C-E04902D339BCQ38814395-309E71E5-A3E8-4522-A782-1596AE2950CDQ39172901-4C4011DF-47BB-4438-8578-CDBC0397363DQ39501076-971262E8-CDE6-407F-AC53-994D1AA4CC1BQ40124899-028032AA-43B4-4FC0-9F1C-2E48599A07FDQ40900248-4ADAB337-BF21-4383-BC69-1CB791315A8FQ40948168-3BBAF181-FE05-4D55-AE7D-A45E9D456CC1Q41257613-E3B137BE-7304-4BF1-AE0E-A001F3194485Q42022992-654B46E6-EE14-4C2C-B12A-CD558421A34CQ42120646-ADC8998F-1DA3-4BC0-A4CC-4C213C96EAAEQ42584529-EB19C4EA-57C7-46C4-9AFA-6E345855CB98Q44625005-3B12F3AC-0984-47B2-A34D-88FFDDA09988Q47146730-2C928165-B62F-4E2E-AD4A-BA32612ED994Q47300891-564A8C27-055D-43FA-9D9F-934A9FA8AB32Q47431069-1B783428-7F9E-4467-864E-2CF927C3FF3DQ53255717-DF80582F-B6F8-44B2-B2E4-FE5068AFE451Q57755485-32AEA689-A8E5-407A-A847-51239491047FQ58217735-6B142283-0072-4E9B-95F7-B6CC3FBE82E3
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Anti-oncogenic potential of the eIF4E-binding proteins.
@en
type
label
Anti-oncogenic potential of the eIF4E-binding proteins.
@en
prefLabel
Anti-oncogenic potential of the eIF4E-binding proteins.
@en
P2093
P2860
P356
P1433
P1476
Anti-oncogenic potential of the eIF4E-binding proteins.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2012.116
P407
P577
2012-04-16T00:00:00Z
P5875
P6179
1049237708